Applications of iPSCs in cancer research

Biomarker Insights

Volumn 10, Issue , 2015, Pages 125-131

  Kim, Jean J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Disease modeling; Induced pluripotent stem cells; Tumorigenesis

Indexed keywords

CANCER CELL; CANCER GROWTH; CANCER RESEARCH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; DISEASE MODEL; EPIGENETICS; FAMILIAL CANCER; GENETIC MANIPULATION; HUMAN; MEDICAL TECHNOLOGY; MOLECULAR MODEL; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; REVIEW; TISSUE ENGINEERING; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84938922843     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMIMI.S20065     Document Type: Review

References (46)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-76.
2. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-72.
3. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-20.
4. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci U S A. 2010;107:14152-7.
5. Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8:409-12.
6. Maekawa M, Yamaguchi K, Nakamura T, et al. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature. 2011;474:225-9.
7. Maekawa M, Yamanaka S. Glis1, a unique pro-reprogramming factor, may facilitate clinical applications of iPSC technology. Cell Cycle. 2011;10:3613-4.
8. Schlaeger TM, Daheron L, Brickler TR, et al. A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2015;33:58-63.
9. Kareta MS, Gorges LL, Hafeez S, et al. Inhibition of pluripotency networks by the rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell. 2015;16:39-50.
10. Krizhanovsky V, Lowe SW. Stem cells: the promises and perils of p53. Nature. 2009;460:1085-6.
11. Liao J, Marumoto T, Yamaguchi S, et al. Inhibition of PTEN tumor suppressor promotes the generation of induced pluripotent stem cells. Mol Ther. 2013;21:1242-50.
12. Banito A, Gil J. Induced pluripotent stem cells and senescence: learning the biology to improve the technology. EMBO Rep. 2010;11:353-9.
13. Banito A, Rashid ST, Acosta JC, et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 2009;23:2134-9.
14. Ramos-Mejia V, Fraga MF, Menendez P. iPSCs from cancer cells: challenges and opportunities. Trends Mol Med. 2012;18:245-7.
15. Lin SL, Chang DC, Chang-Lin S, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 2008;14:2115-24.
16. Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci. 2009;122:3502-10.
17. Miyoshi N, Ishii H, Nagai K, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A. 2010;107:40-5.
18. Carette JE, Pruszak J, Varadarajan M, et al. Generation of iPSCs from cultured human malignant cells. Blood. 2010;115:4039-42.
19. Mathieu J, Zhang Z, Zhou W, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 2011;71:4640-52.
20. Corominas-Faja B, Cufi S, Oliveras-Ferraros C, et al. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle. 2013;12:3109-24.
21. Stricker SH, Feber A, Engstrom PG, et al. Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev. 2013;27:654-69.
22. Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene. 2013;32(18):.e1-21.
23. Liu Y, Cheng H, Gao S, et al. Reprogramming of MLL-AF9 leukemia cells into pluripotent stem cells. Leukemia. 2014;28:1071-80.
24. Hu K, Yu J, Suknuntha K, et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood. 2011;117:e109-19.
25. Kumano K, Arai S, Hosoi M, et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood. 2012;119:6234-42.
26. Gandre-Babbe S, Paluru P, Aribeana C, et al. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood. 2013;121:4925-9.
27. Kim J, Hoffman JP, Alpaugh RK, et al. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep. 2013;3:2088-99.
28. Kotini AG, Chang CJ, Boussaad I, et al. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nat Biotechnol. 2015;33(6):646-55.
29. Lee DF, Su J, Kim HS, et al. Modeling familial cancer with induced pluripotent stem cells. Cell. 2015;161:240-54.
30. Moore JB, Loeb DM, Hong KU, et al. Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line. Front Cell Dev Biol. 2015;3:15.
31. Hochedlinger K, Blelloch R, Brennan C, et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 2004;18:1875-85.
32. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010;19:698-711.
33. Ron-Bigger S, Bar-Nur O, Isaac S, Bocker M, Lyko F, Eden A. Aberrant epigenetic silencing of tumor suppressor genes is reversed by direct reprogramming. Stem Cells. 2010;28:1349-54.
34. Ohnishi K, Semi K, Yamamoto T, et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell. 2014;156:663-77.
35. Broxmeyer HE. Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell. 2010;6:21-24.
36. Xu XH, Zhong Z. Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells. Acta Pharmacol Sin. 2013;34:755-64.
37. Drawnel FM, Boccardo S, Prummer M, et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 2014;9:810-21.
38. Musunuru K. Genome editing of human pluripotent stem cells to generate human cellular disease models. Dis Model Mech. 2013;6:896-904.
39. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318:1920-3.
40. Doulatov S, Vo LT, Chou SS, et al. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. Cell Stem Cell. 2013;13:459-70.
41. Salci KR, Lee JH, Laronde S, et al. Cellular reprogramming allows generation of autologous hematopoietic progenitors from AML patients that are devoid of patient-specific genomic aberrations. Stem Cells. 2015;33(6):1839-49.
42. Sachamitr P, Hackett S, Fairchild PJ. Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy. Front Immunol. 2014;5:176.
43. Wu C, Hong SG, Winkler T, et al. Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies. Mol Ther Methods Clin Dev. 2014;1:14053.
44. Zhong B, Watts KL, Gori JL, et al. Safeguarding nonhuman primate iPS cells with suicide genes. Mol Ther. 2011;19:1667-75.
45. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345:1247125.
46. Graham MJ, Lake BG. Induction of drug metabolism: species differences and toxicological relevance. Toxicology. 2008;254:184-91.